Omeros (NASDAQ:OMER) posted its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04), Fidelity Earnings reports. The company had revenue of $4.61 million during the quarter, compared to analyst estimates of $3.07 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share.
NASDAQ:OMER traded down $3.00 during mid-day trading on Friday, reaching $13.02. The company’s stock had a trading volume of 5,656,225 shares, compared to its average volume of 613,109. Omeros has a twelve month low of $8.36 and a twelve month high of $27.00. The firm has a market cap of $793.47 million, a price-to-earnings ratio of -16.48 and a beta of 3.79.
A number of analysts have issued reports on OMER shares. ValuEngine raised Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 18th. BidaskClub raised Omeros from a “hold” rating to a “buy” rating in a research note on Friday, August 17th. Zacks Investment Research raised Omeros from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Saturday, July 28th. HC Wainwright set a $34.00 price target on Omeros and gave the stock a “buy” rating in a research note on Tuesday, July 24th. Finally, Maxim Group raised their price target on Omeros from $25.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $27.56.
In other Omeros news, VP Marcia S. Kelbon sold 7,529 shares of the firm’s stock in a transaction dated Friday, August 31st. The stock was sold at an average price of $25.75, for a total value of $193,871.75. Following the sale, the vice president now directly owns 227,645 shares of the company’s stock, valued at approximately $5,861,858.75. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 12.10% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “Omeros (OMER) Posts Earnings Results, Misses Expectations By $0.04 EPS” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.thestockobserver.com/2018/11/10/omeros-omer-posts-earnings-results-misses-expectations-by-0-04-eps.html.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Story: What is the Book Value of a Share?
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.